Document is current
Any future updates will be listed below
-
Authors
Zamora, Danniel https://orcid.org/0000-0002-1318-2902
Xie, Hu https://orcid.org/0000-0003-0556-6591
Wong, Elizabeth
Santiano, Clarissa
Vivas-Jimenez, Andrea
Sadowska-Klasa, Alicja
Kampouri, Eleftheria https://orcid.org/0000-0001-8019-3073
Stevens-Ayers, Terry
Ueda Oshima, Masumi https://orcid.org/0000-0003-2277-1976
Leisenring, Wendy M.
Hill, Joshua A. https://orcid.org/0000-0002-7665-7100
Boeckh, Michael https://orcid.org/0000-0003-1538-7984
-
Funding
Funding for this research was provided by:
Merck
U.S. Department of Health & Human Services | National Institutes of Health (T32 AI118690, K23AI163343, K23AI163343, K23AI163343)
- License Information
-
More Information
Article History
Received: 4 February 2025
Revised: 10 April 2025
Accepted: 16 April 2025
First Online: 6 May 2025
Competing interests
: This investigator-initiated study was supported (in part) by research funding from the US National Institutes of Health (NIH, T32 AI118690 [D.Z.], K23AI163343 [D.Z], CA15704 [HX, WL]) and by a Merck & Co., Inc. Investigator Study Program award to MB T-Spot®.CMV test kits were provided by Oxford Immunotec (Abingdon, UK). MB reports grants and personal fees from Merck & Co. and Moderna Therapeutics; personal fees from GlaxoSmithKline, Allovir, Takeda, SymBio, and EvrysBio, all outside the submitted work. EK has participated in advisory board and has received support for conference from Merck.
: All methods were performed in accordance with relevant guidelines and regulations. The study was approved by the Fred Hutchinson Cancer Center Institutional Review Board (FH IRB# 9395). All participants provided written informed consent prior to PBMC collection.
